US67613T1043
US67613T1043
Odyssey Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 2.976.000 | 4.472.000 | 33.5% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 164.132.000 | 139.695.000 | 17.5% | |
| Operating Income | -161.156.000 | -135.223.000 | 19.2% |
| Pretax Income | -149.574.000 | -128.852.000 | 16.1% |
| Net Income Common Stockholders | -148.647.000 | -130.401.000 | 14.0% |
| -- | -- | -- | |
| -- | -- | -- |